Categories AlphaGraphs, Earnings, Technology
Infosys (INFY) Earnings: Q2 profit rises on 21% revenue growth, meets view
Management consulting company Infosys Limited (NYSE: INFY) on Wednesday reported higher revenues and profit for the second quarter of 2022. Earnings matched the consensus estimates, while revenues beat.
The India-based tech firm reported net profit of $733 million or $0.17 per share for the September quarter, which is higher than $653 million or $0.15 per share reported in the prior-year quarter. Earnings matched Wall Street’s expectations.
The income growth was driven by a 21% increase in revenues to $3.99 billion, which marked a faster growth than what was widely expected.
“As we witness a strong market opportunity with global enterprises rapidly accelerating their digital journeys, our sustained investments in expanding capabilities, including the differentiated cloud play, Infosys Cobalt, has uniquely positioned us to continue serving our clients effectively, gain market share and emerge as the preferred cloud and digital transformation partner in the market,” said Salil Parekh, CEO of Infosys.
In the past six months, Infosys’ stock gained about 19%, continuing the uptrend seen since the beginning of the year. The shares moved up early Wednesday following the earnings release, after closing the previous session higher.
Prior Performance
_________________________________________________________________________________________________________________
Stocks you may like:
International Business Machines Corp. (IBM) Stock
_________________________________________________________________________________________________________________
Most Popular
United Parcel Service (UPS) seems on track to regain lost strength
Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company